Lyell Immunopharma, Inc. · NASDAQ:LYEL
Lyell Immunopharma — International Conference on Malignant Lymphoma (ICML) 2025
11 slides from Lyell Immunopharma's conference presentation, Jun 18, 2025
Slide 1: LYL314, a CD19/CD20 CAR T-Cell Candidate Achieves High Rates of Durable Complete Responses in R/R LBCL
LYL314, a CD19/CD20 CAR T-Cell Candidate Enriched for CD62L+ Stem-Like Cells, Achieves High Rates of Durable Complete Responses in R/R Large B-Cell Lymphoma Akil Merchant1, Umar Farooq2, Tahir Latif3, Felix Mensah4, Bradley D. Hunter 5, Locke Bryan6, Stefan O. Ciurea7, Boyu Hu8, William Clark9, Hass
Slide 2: Disclosures
Disclosures Consulting or advisory roles • AbbVie, Amgen, Bristol Myers Squibb, Genmab, Lyell Immunopharma 2
Slide 3: Dual-Targeting CD19/CD20 CAR T-Cells Enriched for Stem-Like Phenotype (CD62L+)
Dual-Targeting CD19/CD20 CAR T-Cells Enriched for Stem-Like Phenotype (CD62L +) LYL314 designed to achieve high complete response rates and long duration of responses LYL314 • LYL314 is a true CD19/CD20 "OR" logic-gated CAR ◦ Designed to target either CD19 and CD20 with full potency, overcome hetero
Slide 4: LYL314 Study Schematic
LYL314 Study Schematic Phase 1/2 multi-cohort, multi-center study in aggressive large B-cell lymphoma (3L+ and 2L CAR-naïve cohorts) LYL314 Infusion Enrollment/ Single Dose Leukapheresis 100 x 106 CAR T cells Lymphodepletion Optional Flu 30 mg/m2 Post-treatment Response Assessment Bridging Therapy C
Slide 5: High-Risk, Heavily Pre-Treated, Multi-Center US Patient Population
High-Risk, Heavily Pre-Treated, Multi-Center US Patient Population Key patient demographics and baseline disease characteristics 3L+ 2L 3L+ 2L Characteristics N = 34 N = 17 Characteristics N = 34 N = 17 Median (range) age, years 65 (21, 87) 69 (44 , 85) Primary refractory, n (%) 16 (47%) 14 (82%) ≥
Slide 6: Overall Response Rate of 88% and Complete Response Rate of 72% (3L+ LBCL)
Overall Response Rate of 88% and Complete Response Rate of 72% (3L+ LBCL) High rate of durable complete responses Best Overall Response (3L+) N = 25 • 71% (10/14) of patients with complete response remained in complete response Overall Responses, n (%) 22 (88%) at ≥ 6 months Complete Responses, n (%
Slide 7: Durable Responses in Patients with 3L+ R/R LBCL
Durable Responses in Patients with 3L+ R/R LBCL 71% of patients with complete response remained in complete response at ≥ 6 months Data cutoff: April 15, 2025 7
Slide 8: High Overall Response Rate in Patients with 2L LBCL
High Overall Response Rate in Patients with 2L LCBL High-risk characteristics with 91% of patients with primary refractory disease Best Overall Response (2L) N = 11 Overall Responses, n (%) 10 (91%) Complete Responses, n (%) 7 (64%) Partial Response, n (%) 3 (27%) Stable Disease, n (%) 1 (9%) Median
Slide 9: Manageable Safety Profile Allowing for Outpatient Administration
Manageable Safety Profile Allowing for Outpatient Administration Adverse events of interest (3L+ and 2L LBCL) Adverse Event, n (%) N = 51 Adverse Event, n (%) N = 51 CRS IEC-HS Grade 1 11 (22%) Grade 1or 2 1 (2%) Grade 2 18 (35%) Grade ≥ 3 0 (0%) Grade ≥ 3 0 (0%) Infections Median time to onset, day
Slide 10: Robust CAR T-Cell Expansion Resulting in Rapid and Durable B-Cell Depletion
Robust CAR T-Cell Expansion Resulting in Rapid and Durable B-Cell Depletion 95% of final drug product is CD62L+ (naïve T cells) CAR T-Cell Expansion B-Cell Depletion Final Drug Product LYL314 Copies per g DNA %CD62L+ of CD3+ Cells %CD3+ of Viable Cells Cells/l Time Post LYL314 Administration (Days
Slide 11: LYL314 is a Promising CAR T-Cell Candidate for Large B-Cell Lymphoma
LYL314 is a Promising CAR T-Cell Candidate for Large B-Cell Lymphoma Results from a Phase 1/2 multi-center study evaluating LYL314 in 3L+ and 2L CAR-naïve patients • High response rates in high-risk patients o Overall response rate of 88% and a complete response rate of 72% in the 3L+ setting • High
Lyell Immunopharma — International Conference on Malignant Lymphoma (ICML) 2025 on 6ix